Travere Therapeutics, Inc. (TVTX)

Market Cap	1.51B
Revenue (ttm)	333.87M
Net Income (ttm)	-169.06M
Shares Out	89.14M
EPS (ttm)	-2.00
PE Ratio	n/a
Forward PE	216.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,841,139
Open	16.97
Previous Close	16.91
Day's Range	16.55 - 17.34
52-Week Range	8.09 - 25.29
Beta	0.75
Analysts	Strong Buy
Price Target	33.40 (+97.17%)
Earnings Date	Aug 6, 2025

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 385
• Stock Exchange: NASDAQ
• Ticker Symbol: TVTX
• Website: https://www.travere.com

Financial Performance

In 2024, Travere Therapeutics's revenue was $233.18 million, an increase of 60.55% compared to the previous year's $145.24 million. Losses were -$321.55 million, 188.6% more than in 2023.

Analyst Summary

According to 16 analysts, the average rating for TVTX stock is "Strong Buy." The 12-month stock price target is $33.4, which is an increase of 97.17% from the latest price.

Price Target

$33.4

(97.17% upside)

Analyst Consensus: Strong Buy